ARVO

ARVO 2017 awards in spotlightAs eye and vision researchers gather this month for the 2017 meeting of the Association for Research in Vision and Ophthalmology (ARVO), four members will be recognized for their contributions to ophthalmology and vision research with a 2017 ARVO Achievement Award and lecture.
Researchers, scientists flock to East Coast for ARVO 2017The annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) continues to explore new cities after spending many years in Fort Lauderdale, FL. This year’s installment will be held May 6 to 11 at the Baltimore Convention Center, and will feature the theme “Global Connections in Vision Research,” in recognition of the fact that successful science requires strong global connections--among researchers, across disciplines, and between generations.
Study tracks clinical use of dexamethasone implant for DMEA 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.
IL-1 receptor inhibitor fails on ocular itching endpointIsunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.
Getting ready for ARVO 2017: New president, special OCT issueLearn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond.
10 things you may have missed at ARVO
10 things you may have missed at ARVOFrom blueberries for dry eye, to advances in "robotic" vision, here are some highlights from ARVO 2016.
ARVO 2015 Making powerful connections in vision research, online networkingMore than 11,000 clinicians and researchers will gather in Denver to learn more about leading eye and vision research at the 2015 meeting of the Association for Research in Vision and Ophthalmology.
Popular diabetes drug linked to reduced glaucoma riskA recent study found that metformin (Glumetza, Salix), a popular diabetes drug, is associated with a dose-dependent risk reduction for open-angle glaucoma.
Results from lantanoprostene bunod clinical studies presented at ARVOThe results of 2 clinical studies on latanosprostene bunod—CONSTELLATION and KRONUS— were presented during the Association for Research in Vision and Ophthalmology meeting last week.
Eleven Biotherapeutics presents data on protein therapeutics for anterior, posterior eye diseasesDuring the Association for Research in Vision and Ophthalmology meeting last week, Eleven Biotherapeutics presented data for 2 of its protein therapeutics, which demonstrate the role of cytokine biology to target both anterior and posterior eye diseases.